玻璃体腔注射Lucentis治疗视网膜静脉阻塞继发黄斑水肿的临床疗效观察

目的评估玻璃体腔注射Lucentis治疗视网膜静脉阻塞（retinalveinocclusion，RVO）继发黄斑水肿的疗效。方法回顾性分析玻璃体腔注射Lucentis治疗视网膜静脉阻塞继发黄斑水肿患者16例（16眼）。治疗前及治疗后1、2、3d和1、4、12周进行最佳矫正视力（BCVA）、眼压、裂隙灯及间接检眼镜检查。治疗前及治疗后4周、12周行光学相干断层扫描（OCT）、荧光素眼底血管造影（FFA）检查。对比分析治疗前后患者视力及黄斑中心视网膜厚度（CMT）的改变。结果玻璃体腔注射Lucentis治疗4周、12周患者最佳矫正视力均提高，差异均有统计学意义。玻璃体腔注射Lucentis治疗4周、12周患者CMT平均值均有明显降低。整个治疗及随访中所有患者均未见与注射及药物有关的眼部和全身不良反应。结论玻璃体腔注射Lucentis治疗视网膜静脉阻塞继发黄斑水肿短期安全有效，未见明显不良反应。

The clinical study on intravitreous injection of Lucentis for macular ede- ma caused by retinal vein occlusion

Objective To evaluate the clinical efficacy of Lucentis on macular edem caused by RVO. Methods A ret- rospective observation about 16 patients （16eyes） with macular edema caused by RVO received intravitreal injection of Lucentis. Through the collection of clinical data in patients （best corrected visual acuity, Optical coherence tomog- raphy and fluoresce infundus angiography） with before injection and 4, 12 weeks after injection, comparative analysis the changes in best-corrected visual acuity and central macular retinal thickness （CMT） between before and after treatment. Results Intravitreal injection of Lueentis treatment for 4 weeks and 12 weeks, all the patients~ best-cor- rected visual acuity were improved, and the CMT average were significantly lower, the differences were statistically sig- nificant. In the period of treatment and follow-up, all the patients showed no injection and drug-related ocular and systemic adverse reactions. Conclusion Intravitreal injection of Lucentis is safe and effective form macular edem caused by RVO in the short term, and no significant adverse reactions.